Bio-Gene raises A$3.28M to fund bio-insecticide push
What's the deal? Bio-Gene TechnologyDealroom has a profile for this one. Try Dealroom → (ASX:BGT) has completed a A$3,275,000 (about $2.3 million) private placement and share purchase plan, the Melbourne-based company said on August 10, 2026. It issued 51,980,000 fully paid ordinary shares to raise the gross proceeds before costs.
Why now? The raise concludes Tranche 2 of a placement first announced on May 26, 2025, and cleared by shareholders at an extraordinary general meeting on August 5, 2026.
What's the endgame? Bio-Gene develops bio-insecticides based on a naturally occurring class of compounds designed to counter insecticide resistance. It says its products apply across crop protection, grain storage, public health, animal health, and consumer uses.
What else? Shareholders also approved 69,221,150 options exercisable at 3.5 cents, expiring October 15, 2027, issued to placement and SPP participants and the lead manager.
The signal: At roughly $2.3 million, the round sits in the smaller tier of disclosed raises — near the 15th percentile by amount — reflecting the modest, milestone-driven funding typical of early-stage agtech firms building toward commercialisation.
Read more: Listcorp
Image credit: aqua.mech
